PreludeDx™ Presents New Data at the 40th Annual Miami Breast Cancer Conference Identifying Which Patients with DCIS May Be Undertreated Based on Clinicopathologic Factors Alone

March 2, 2023 Los Angeles Biotechnology Network News Los Angeles Biotech News Comments Off on PreludeDx™ Presents New Data at the 40th Annual Miami Breast Cancer Conference Identifying Which Patients with DCIS May Be Undertreated Based on Clinicopathologic Factors Alone

Using 10-yr Outcomes Data, DCISionRT Reclassified Nearly 70% of CP Model Low-Risk Patients to Elevated Risk LAGUNA HILLS, Calif., March 2, 2023 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today...

Click to view original post